pharmacology of hemostasis disorder

8/18/2019 Pharmacology of Hemostasis Disorder

1/11

“Pharmacology of drugs in hemostatic disorder”

1. Which one of following is true about HeparinA. It has thrombolytic activity

B. It has most prolonged activity when given orally

C. It acts by binding to AT III!. It inhibits the aggregation of platelets caused by T"A#

$. It acts by bloc%ing hepatic vitamin & regeneration

A'(W$)* C

#. Warfarin *A. Acts rapidly when given orally

B. Is potentiated by barbiturates

C. Is antagoni+ed by protamine sulfate

!. Affects the activity of clotting factors

$. Is potentiated by platelet factor I,

A'(W$) * !

-. The ris% of bleeding in patients receiving heparin is increased by aspirin because aspirin*

A. Inhibits heparin anticoagulant activityB. Inhibits platelet function

C. !isplaces heparin from plasma protein/binding sites

!. Inhibits prothrombin formation

$. Causes thrombocytopenia

A'(W$) * B

0. Aspirin can *

A. revent the formation of T"A#

B. rolong the whole blood clotting timeC. (horten the bleeding time

!. Inhibit fibrinolysis

$. Inhibit the effects of warfarin

A'(W$) * A

2. Which of the following may cause increased bleeding as a serious unwanted side effect3A. Warfarin A'(W$)* $

B. Heparin

C. Aspirin!. Tissue plasminogen activator

$. All of the above

4. (pecific antidote of Heparin is

A. Aspirin A'(W$) * C

B. ,itamin &

C. rotamine

!. Coumarin derivative $. Warfarin


2/11

5. 6ver dose of Heparin can be handled by giving

A. rotamin sulphate

B. (trepto%inaseC. Aspirin

!. !ipiridamol

$. 7ro%inase

A'(W$)* A

8. (pecific antidote of (trepto%inase

A. Aspirin

B. Coumarin

C. Aminocaproic acid!. 9erritin

$. Warfarin

A'(W$) * B

:. The inducer of platelet aggregation isA. Adenosine monophosphate

B. Adenosine diphosphate

C. Adenosine triphosphate!. Trigliseride

$. 9atty acid

A'(W$) * B

1;. 9ollowing are factors influenced by vitamin & $"C$T

A. AntithrombinB. Christmas factor

C. 9actor II

!. (tuart factor $. roconvertin

A'(W$) * A

11. 9ollowing are true about 'aftoarge amount of alcohol at one time

$. Amiodarone

A'(W$) * B


3/11

1-. Aspirin is used in the treatment of

A. Arterial thrombotic

B. ,enous thromboticC. Thrombo?ane synthesis

!. >ipo?igenase synthesis

$. Cycloo?igenase synthesis

A'(W$) * A

10. 9ollowing are the inhibitor of platelet activity $"C$T

A. Aspirin

B. Carba+ochrome

C. !ipiridamol!. (ulfinpira+one

$. !e?tran

A'(W$) * B

12. Warfarin is not used in the treatment of

1. 7nstable angina after myocardial infarction

#. $mbolism after hip surgery-. Arterial rethrombosis after thrombolysis

@0. ulmonary embolism in pregnancy

A'(W$) * !

14. (trepto%inase causes bleeding by attac%ing

@1. 9ibrinogen@#. 9actor ,

@-. 9actor ,III

0. 9actor "

A'(W$) * A

15. The action of antithrombotics@1. latelet aggregation inhibitors

@#. (upress platelet function

@-. revent platelet aggregation 0. Increase T"A# synthesis

A'(W$) *A

18. !aily inta%e of aspirin is for

@1. Its anti/clotting effect

@#. The inhibition of thrombo?ane synthesis@-. )educing the ris% of myocardial infarction

@0. Its bloc%ade of platelet cycloo?igenase

A'(W$)* $


4/11

1:. The anti clotting effect of aspirin is long lived B$CA7($ platelet lac% of nucleus and

do not ma%e new en+yme

A'(W$) * True ///// True and has a relationship

#;. $ndogenous heparin can not be detected in the blood B$CA7($ heparin is released

from mast cells

A'(W$) * True ///// True but has not relationship

#1. Anticoagulant action both in vitro in vivo is seen with

A. $!TA

B. Heparin

C. Coumarin

!. henondione

##. henylbuta+one enhances the anticoagulant effect of dicoumarol by

A. reventing hepatic transport of vit. & B. reventing vit. & synthesis

C. reventing vit. & absorption

D. Displacing dicoumarol from protein binding

#-. Which of the following drugs may produce neutropenia leading to agranulocytosis3

A. Corticosteroids

B. enylbuta+one

C. ,incristin!. Halothane

#0. Action of heparin is potentiated byA. 'arcotics

B. NSAD

C. Analgesic!. Warfarin

#2. =ethaemoglobinemia can be caused by all $"C$T

A. (ulfonamides

B. Phenytoin

C. henactin

!. (alicylates

#4. In dicumarol poisoning which vit & is used

A. =enadioneB. =ena


5/11

#8. The anti clotting effect of aspirin is long lived B$CA7($ platelet lac% of nucleus anddo not ma%e new en+yme

A'(W$) * True ///// True and has a relationship

#:. $ndogenous heparin can not be detected in the blood B$CA7($ heparin is releasedfrom mast cells

A'(W$) * True ///// True but has not relationship


6/11

“ Pharmacological aspect of anemia”

1. Before beginning folate therapy for megaloblastic anemia one should consider which ofthe following to prevent neurological disease3

A. ,itamin B1# deficiency

B. inc deficiencyC. Iron deficiency

!. ,itamin B4 deficiency

$. ,itamin & deficiency

A'(W$) * A

#. Iron can be absorbed as

A. 9erri ion

B. 9erritin

C. Apoferritin

!. 9erro ion$. rotoporfirin

A'(W$) * !

-. The absorption of orally Cyanocobalamine needsA. Intrinsic factor of Castle

B. $?trinsic factor of Castle

C. 9olic acid

!. )'A$. !'A

A'(W$) * A

0. Antagonist of 9olic acid in neoplasmata is

A. CyanocobalamineB. ,itamin B1#

C Aminopterin

!. Iron$. Aspirin

A'(W$) * C

2. Antidotum of iron to?icity is

A. Hemosiderin

B. 9errosulphateC. 9erritin

!. !efero?amine

$. 9olic acid

A'(W$) * !

4. Which of the following vitamins needs intrinsic factorD for its absorption

A. ,itamin CB. ,itamin B1#

C. ,itamin !


7/11

!. ,itamin A

$. ,itamin &

A'(W$) * B

5. arenteral iron formulation for iron deficiency that may only be given intramuscularlyA. Iron sulphate

B. Iron fumarate

C. Iron gluconate!. Iron de?tran

$. Iron sorbitol

A'(W$) * $

8. The most common cause of failure to respond to oral iron therapy is*

A. 9ailure of bone marrow to produce ade


8/11

A. Chloramphenicol

B. Cyclosporin

C. "ld # degraded tetracycline!. !ecreased pseudocholineesterase

1-. All of the following can cause macrocytic anemia $"C$TA. =ethotre?ate

B. yrimethamine

C. Trimethoprim

D. Pentamidine

10. ,itamin B1# deficiency can be caused by all of the following except

A. ollinger $llison syndrome A'(W$) * !B. 9ish tapeworm

C. Blind loop syndrome

!. >iver disease

$. Intestinal malabsorption

12. arenteral iron formulation for iron deficiency that may only be given intramuscularlyA. Iron sulphate A'(W$) * $

B. Iron fumarate

C. Iron gluconate!. Iron de?tran

$. Iron sorbitol

14. 9ollowing drugs can cause haemolytic anemia in association with G4! $"C$TA. =epacrine

B. uinine

C. Antipyrine

D. $%D"PA

15. 9ollowing information are true about Hematinics $"C$TA. Improve the


9/11

B. )emoving iron from hemosiderin

C. )emoving iron from ferritin

D. &emo*ing iron from hemoglobin

#1. Increased folate re/!6A

$. !imercaprol


10/11

etunEu%* ilih satu Eawaban yang paling tepat

1. Besi diabsorbsi dalam bentu%*A. 9eri !D. )ero

B. 9eritin $. rotoporfirin

C. Apoferitin

#. !osis Besi yang diberi%an secara bertahap %epada penderita anaemia yang tida%

mempunyai simpanan 9e serta hanya mempunyai Hb 1; g J

A. 2;; mg !. 1#2; mg

B. 52; mg !(. +,-- mg

C. 1;;; mg

-. Absorbsi (iano%obalamin yang diberi%an per oral memerlu%an

A. “ntrinsic factor of Castle” !

B. $?trinsic factor of CastleD

C. Asam 9olat

D. )'A

(. !'A

0. Antagonis asam folat pada neoplasmata ialah

A. (iano%obalamin

B. ,itamin B1#

C. Aminopterin !

D. Besi

2. !erivat 'aftoI

A. =enstimulasi produ%si rotrombin

B. enghambat produ/si Pro/on*ertin !

C. (inonimnya ialah ,itamin &

!. Terdapat dalam flora usus

$. reparat sintetisnya ialah =enadion


11/11

4. Antidotum spesifi% Heparin ialah

A. Aspirin

B. ,itamin &

C. Protamine !

!. !erivat &umarin

$. Warfarin

5. ernyataan ini benar tentang HeparinA. =empunyai a%tivitas tromboliti%

B. TerEadi perpanEangan a%tivitas bila diberi%an secara oral

C. e/anisme /er0anya ialah dengan cara beri/atan dengan A1 2 !

!. =enghambat agregasi platelet yang disebab%an oleh T"A#$. Be%erEa dengan caar memblo% regenerasi vitamin & hepati%

8. )isi%o perdarahan pada penderita yang mendapat pengobatan heparin a%an mening%at

oleh aspirin %arena aspirin

A. menghambat a%tivitas anti%oagulan heparin

B. enghambat fungsi platelet !

C. =elepas%an heparin dari i%atannya dengan protein plasma

!. =enghambat pembentu%an protrombin

$. =enimbul%an trombositopenia

:. (ifat Aspirin *

A. ecegah pembentu/an 13A4 !

B. =emperpanEang whole blood clotting timeD

C. =emperpende% wa%tu perdarahan

!. =enghambat fibrinolisis$. =enghambat efe% warfarin

1;. (ubstansi di bawah ini mening%at%an risi%o perdarahan yang serius

A. WarfarinB. Heparin

C. Aspirin

!. Tissue plasminogen activator

(. Semuanya benar !

pharmacology of hemostasis disorder

Documents